Drug Profile

NBG 035

Alternative Names: NBG-035

Latest Information Update: 03 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NB Health Laboratory
Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
Mechanism of Action G protein-coupled receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer; Retinal disorders

20 Jul 2023 NBG 035 is available for licensing as of 20 Jul 2023. https://nbhl.co.jp/partnering/
20 Jul 2023 Early research in Cancer in Japan (Parenteral), prior to July 2023 (NB Health Laboratory pipeline, July 2023)
20 Jul 2023 Early research in Retinal disorders in Japan (Parenteral), prior to July 2023 (NB Health Laboratory pipeline, July 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com